Recently Featured

GSK and SBP Group Collaborate to Accelerate Bepirovirsen Launch in China

May 18, 2026
GSK has entered into a strategic partnership with SBP Group, through its subsidiary CTTQ, to expedite the launch of bepirovirsen, a promising treatment for chronic hepatitis B patients in China. This collaboration underscores the growing urgency to address the significant public health challenge posed by hepatitis B, which affects millions in the region. The partnership…

PCOS’s new name is PMOS, a small letter change that required a big scientific process

May 17, 2026
PCOS is officially rebranded as PMOS, marking a significant shift in the understanding of this prevalent metabolic condition affecting women. This change, announced on Tuesday, may appear minor at first glance, yet it encapsulates over a decade of rigorous scientific discourse aimed at refining the terminology used to describe what was previously known as polycystic…

Partner Therapeutics secures FDA approval for Bizengri

May 17, 2026
Partner Therapeutics has received FDA approval for Bizengri, a significant advancement in the treatment of adults with advanced, unresectable or metastatic cholangiocarcinoma characterized by an NRG1 gene fusion. This approval is particularly noteworthy as it addresses a critical need for patients who have experienced disease progression following prior systemic therapy. The approval of Bizengri reflects…

EMA Welcomes Political Agreement on Critical Medicines Act

May 17, 2026
The European Medicines Agency (EMA) has expressed support for the provisional agreement reached by the European Parliament and the Council of the European Union regarding the proposed Critical Medicines Act (CMA). This legislative framework aims to enhance the resilience and security of supply chains for critical medicines, which is increasingly vital in the face of…

Ongoing Cases